This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Nuvo Pharmaceuticals (Ireland) Designated Activity Company
Nuvo Pharmaceuticals (Ireland) Designated Activity Company, commonly referred to as Nuvo, is a prominent player in the pharmaceutical industry, headquartered in Ireland (IE). Founded in 2014, the company has rapidly established itself in the global market, focusing on innovative pain management solutions and specialty pharmaceuticals. With a strong operational presence in Europe and North America, Nuvo is dedicated to developing and commercialising unique therapeutic products. Its core offerings include the well-regarded Pennsaid® and other proprietary formulations that stand out for their efficacy and patient-centric design. Nuvo's commitment to research and development has led to significant milestones, positioning the company as a leader in its field. With a focus on improving patient outcomes, Nuvo Pharmaceuticals continues to make strides in the healthcare landscape, earning recognition for its contributions to pain management and specialty care.
DitchCarbon Score
How does Nuvo Pharmaceuticals (Ireland) Designated Activity Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nuvo Pharmaceuticals (Ireland) Designated Activity Company's score of 34 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Nuvo Pharmaceuticals (Ireland) Designated Activity Company currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Apotex Inc., and any emissions data would be inherited from this parent organization. However, no specific emissions figures or reduction targets have been provided. In terms of climate commitments, Nuvo Pharmaceuticals has not outlined any specific reduction initiatives or targets, such as those set by the Science Based Targets initiative (SBTi). The lack of documented climate pledges or reduction strategies suggests that the company may still be in the early stages of developing a comprehensive climate action plan. As a subsidiary, Nuvo Pharmaceuticals may align its environmental strategies with those of Apotex Inc., but without explicit data or commitments, it is challenging to assess their current climate impact or future goals. The company operates within an industry context that increasingly prioritises sustainability and carbon footprint reduction, indicating potential future developments in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 44,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nuvo Pharmaceuticals (Ireland) Designated Activity Company is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
